cannabis

L.A. Measure CB voter guide: taxing illegal cannabis businesses

p]:text-cms-story-body-color-text clearfix”>

A nonprofit advocacy group, Social Equity LA, organized with local cannabis business owners to oppose the measure in letters to Mayor Karen Bass.

Luis Rivera, executive director of the nonprofit, said Measure CB risks legitimizing the illegal cannabis industry while linking city finances to the tax revenue the businesses would generate. The measure also would undermine Proposition 64, the state law that requires cannabis businesses to be licensed, he said. And amid the city’s struggles to track and close illegal cannabis businesses, Rivera said it will be difficult to force them to pay up.

“There’s no guarantee or mechanism to assure that illegal operators will pay the taxes or fulfill their obligations,” Rivera said.

Even if they pay taxes, illegal operators could undercut legal businesses by selling unregulated products and avoiding requirements, such as code inspections and safety tests for merchandise, that legal businesses must fulfill to keep their licenses, he said. For an already struggling industry, the answer isn’t taxing more businesses, he said — it’s lowering taxes.

Source link

Cannabis Policy Shift in US Doesn’t Move the Money

The White House’s long-anticipated cannabis regulatory shake-up may ease rules on paper, but for banks, processors, and payment networks, little changes in practice.

While the rescheduling of cannabis from Schedule I to Schedule III has sparked hope for industry reform, the reclassification doesn’t change the ongoing banking hurdles for smaller cannabis businesses in the U.S.

As large, publicly traded multi-state operators (MSOs) secure banking access, the majority of smaller cannabis companies still operate in a cash-only environment, with federal illegality, strict anti-money laundering rules, and a stalled bill blocking wider access to financial services. Alan Brochstein, an Austin, Texas-based analyst and founder of marketing firm New Cannabis Ventures, told Global Finance that meaningful reform still hinges on the passage of the SAFER Banking Act.

“Just because you’re Schedule III instead of Schedule I, you’re still federally illegal,” he said, referring to an April 23 order signed by Todd Blanche, President Donald Trump’s acting attorney general.

The reclassification formally recognizes cannabis for medical use. But the shift stops short of legalization and serves as a sobering reminder of the legal ambiguity that has kept major financial players wary.

“So, I don’t think that’s going to change,” Brochstein said. “Visa and Mastercard won’t allow processing, [and] rescheduling doesn’t change that.”

The bipartisan SAFER Banking Act, proposed in 2023, would provide a safe harbor for financial institutions serving state-sanctioned cannabis businesses, Brochstein explained. Lawmakers designed the bill to shield banks and credit unions from federal penalties and asset forfeiture when working with legal operators in compliant states. It remains stalled in Congress.

The reclassification has its benefits—expanding research, reducing tax burdens, and further legitimizing state medical programs across 40 states. Cannabis operators, however, remain boxed out of mainstream banking. Lenders, card networks, and cross-border investors are unlikely to change their stance substantially.

Regulatory Change, Financial Stagnation

For now, rescheduling grants medical cannabis some legitimacy, but the financial plumbing that underpins the industry remains frozen. As a result, operators rely on cash-heavy systems and state-by-state workarounds, especially in markets where recreational sales dominate revenue.

“I don’t think the banking landscape will change that much at this time,” said Richard Ormond, a partner at Los Angeles-based law firm Buchalter, capturing the industry’s central tension as financial institutions stay on the sidelines.

“Things will remain cautious as the majority of businesses, particularly in California, really focus on recreational use rather than just medical use,” Ormond predicted.

A broader review is coming, with Congressional hearings on the SAFER Act scheduled for June. Until then, cannabis suppliers are left with incremental progress on regulation—and persistent uncertainty in the banking system. 

Source link

Trump reclassifies state-licensed medical marijuana as a less-dangerous drug

President Trump’s acting attorney general on Thursday signed an order reclassifying state-licensed medical marijuana as a less-dangerous drug, a major policy shift long sought by advocates who said cannabis should never have been treated like heroin by the federal government.

The order signed by Todd Blanche does not legalize marijuana for medical or recreational use under federal law. But it does change the way it’s regulated, shifting licensed medical marijuana from Schedule I — reserved for drugs without medical use and with high potential for abuse — to the less strictly regulated Schedule III. It also gives licensed medical marijuana operators a major tax break and eases some barriers to researching cannabis.

The Trump administration also said it was jump-starting the process for reclassifying marijuana more broadly, setting a hearing to begin in late June.

Trump told his administration in December to work as quickly as possible to reclassify marijuana. On Saturday, as the Republican president signed an unrelated executive order about psychedelics, he seemed to express frustration that it was taking so long.

Blanche said Thursday that the Department of Justice was “delivering on President Trump’s promise” to expand Americans’ access to medical treatment options. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” he said in a statement.

What the marijuana reclassification order does

Blanche’s action largely legitimizes medical marijuana programs in the 40 states that have adopted them. It sets up an expedited system for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration.

It makes clear that cannabis researchers won’t be penalized for obtaining state-licensed marijuana or marijuana-derived products for use in their work, and it grants state-licensed medical marijuana companies a windfall by allowing them, for the first time, to deduct business expenses on their federal taxes.

Any marijuana-derived medicine approved by the Food and Drug Administration is similarly listed in Schedule III, it said.

Since 2015, Congress has prohibited the Justice Department from using its resources to shut down state-licensed medical marijuana systems. But the order nevertheless represents a major policy shift for the U.S. government, which has continued its long-standing marijuana prohibition — dating to the Marihuana Tax Act of 1937 — even as nearly all the states have approved cannabis use in some form.

Two dozen states plus Washington, D.C., have authorized adult recreational use of marijuana, 40 have medical marijuana systems, and eight others allow low-THC cannabis or CBD oil for medical use. Only Idaho and Kansas ban marijuana outright.

The regulation of medical marijuana has come a long way since California became the first state to adopt it in 1996, Blanche wrote.

“Today the vast majority of States maintain comprehensive licensing frameworks governing cultivation, processing, distribution, and dispensing of marijuana for medical purposes,” Blanche wrote. “Taken as a whole, they demonstrate a sustained capacity to achieve the public-interest objectives … including protecting public health and safety and preventing the diversion of controlled substances into illicit channels.”

The president of the American Trade Assn. for Cannabis and Hemp, Michael Bronstein, called it “the most significant federal advancement in cannabis policy in over 50 years.”

“This action recognizes what Americans have long known, cannabis is medicine,” he said in a written statement.

Critic calls the order ‘a tax break to Big Weed’

The Trump administration’s decision drew derision from marijuana legalization opponent Kevin Sabet, the chief executive of Smart Approaches to Marijuana. Sabet said that while marijuana research is necessary, “there are many ways to increase our knowledge without giving a tax break to Big Weed and sending a confusing message about marijuana’s harms to the American public.”

“With this move, we are now confronted with the most pro-drug administration in our history,” Sabet said in a text message. “Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction.”

Marijuana or marijuana-derived products that are not distributed through a state medical marijuana program will continue to be classified in Schedule I.

Schedule III drugs are defined as having moderate to low potential for physical and psychological dependence. Some critics of the industry have suggested that legalization in the states has led to stronger and stronger cannabis products, which need to be researched rather than categorized less strictly than before.

The efforts to reclassify marijuana

The Justice Department under President Biden had proposed to reclassify marijuana, eliciting nearly 43,000 formal public comments. The DEA was still in the review process when Trump succeeded Biden, and Trump ordered that process to move along as quickly as legally possible.

Blanche’s order sidestepped the review process by relying on a provision of federal law that allows the attorney general to determine the appropriate classification for drugs that the U.S. must regulate pursuant to an international treaty.

It was unclear how the order might affect operations in states where licensed recreational marijuana shops also sell to medical patients. In Washington state, which in 2012 became one of the first states to legalize the adult use of marijuana, 302 of 460 licensed stores have endorsements allowing them to sell tax-free cannabis products to registered patients.

Many Republicans oppose loosening marijuana restrictions. More than 20 Republican senators, several of them staunch Trump allies, signed a letter last year urging the president to keep the current standards.

Trump has made his crusade against other drugs, especially fentanyl, a feature of his second term, ordering U.S. military attacks on Venezuelan and other boats the administration insists are ferrying drugs. He signed another executive order declaring fentanyl a weapon of mass destruction.

Richer and Johnson write for the Associated Press. Johnson reported from Seattle.

Source link